Abstract

The present invention relates to a sustained release pharmaceutical composition capable of forming in-situ implants and a preparation method therefor and, to a sustained release pharmaceutical composition capable of forming in-situ implants and a preparation method therefor, in which goserelin and a biodegradable polymer are each prepared into a sol state by being dissolved in a pharmaceutically acceptable solvent, and quickly transform into a solid state on a site after being administered thereto, so that initial drug release is suppressed and at the same time drug efficacy can be maintained for a long time period of more than one month with a single injection.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 38/09 - Luteinising hormone-releasing hormone [LHRH]Related peptides
• A61P 35/00 - Antineoplastic agents

Goods & Services

Pharmaceutical preparations for treating sensory organ disorders; oral antiseptic; gargles for medical purposes; pharmaceutical preparations for treating gastrointestinal diseases; pharmaceutical preparations for treating cardiovascular diseases; pharmaceutical preparations for the central nervous system; pharmaceutical preparations for dental purposes; medicines for periodontal diseases; hormones for medical purposes; pharmaceutical preparations for respiratory diseases.

Abstract

The present invention provides: a hyaluronic acid crosslinked product having both monophasic and biphasic characteristics; and, as a preparation method therefor, a method for preparing a granulated monophasic hyaluronic acid crosslinked product. The hyaluronic acid crosslinked product is characterized in that the ratio of viscosity and modulus of elasticity is 4:1 to 2:1. The hyaluronic acid cross-linked product of the present invention may be used as an injection in tissue.

IPC Classes  ?

• A61L 27/20 - Polysaccharides
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol

Abstract

The present invention relates to a composition for parenteral administration, containing donepezil as an active ingredient, and a preparation method therefor. Donepezil, which has been conventionally used for oral or transdermal administration, is prepared as microparticles comprising a biodegradable and biocompatible polymer and a release controller so as to be provided as a pharmaceutical composition for sustained release parenteral administration, thereby enabling in vivo sustained release continuously for 2-12 weeks or more. Therefore, it is possible to reduce the frequency of administration to a patient and maintain an effective concentration in the blood for a long time.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to a composition for parenteral administration, containing donepezil as an active ingredient, and a preparation method therefor. Donepezil, which has been conventionally used for oral or transdermal administration, is prepared as microparticles comprising a biodegradable and biocompatible polymer and a release controller so as to be provided as a pharmaceutical composition for sustained release parenteral administration, thereby enabling in vivo sustained release continuously for 2-12 weeks or more. Therefore, it is possible to reduce the frequency of administration to a patient and maintain an effective concentration in the blood for a long time.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 9/14 - Particulate form, e.g. powders

Abstract

Provided is a process for preparing Voriconazole represented by Chemical Formula 1. More particularly, the process for preparing Voriconazole of Chemical Formula 1 includes: carrying out the Reformatsky-type coupling reaction between a ketone derivative of Chemical Formula 4 and a pyrimidine derivative of Chemical Formula 5 to obtain a compound of Chemical Formula 3; reacting the substituents halo and oxysulfonyl with a hydrogen donor to obtain racemic Voriconazole of Chemical Formula 2; and carrying out optical isolation of the racemic Voriconazole by adding an adequate optically active acid thereto to obtain Voriconazole having high optical purity with high cost-efficiency and high yield.

IPC Classes  ?

• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Provided is a process for preparing Voriconazole represented by Chemical Formula 1. More particularly, the process for preparing Voriconazole of Chemical Formula 1 includes: carrying out the Reformatsky-type coupling reaction between a ketone derivative of Chemical Formula 4 and a pyrimidine derivative of Chemical Formula 5 to obtain a compound of Chemical Formula 3; reacting the substituents halo and oxysulfonyl with a hydrogen donor to obtain racemicVoriconazole of Chemical Formula 2; and carrying out optical isolation of the racemicVoriconazole by adding an adequate optically active acid thereto to obtain Voriconazole having high optical purity with high cost-efficiency and high yield.

IPC Classes  ?

• C07D 403/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings
• C07D 403/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing alicyclic rings

Abstract

The present invention relates to a composition comprising the extract of Prunella vulgaris L for preventing and treating ADHD and the use thereof.

IPC Classes  ?

• A61K 36/536 - Prunella or Brunella (selfheal)
• A23L 1/30 - containing additives (A23L 1/308 takes precedence);;
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Disclosed is a method for preparing a longer sustained-release formulation containing bioactive substances. More particularly, the present invention provides a method for preparing longer sustained-release microcapsules comprising: adding an emulsion including bioactive substances, biocompatible polymer and polyvinylpyrrolidone to an aqueous solution.

IPC Classes  ?

• A61K 9/50 - Microcapsules

Abstract

The present invention relates to a method for manufacturing a sustained release microsphere which is able to continuously control the release of a drug. More specifically, the present invention relates to a method for manufacturing a sustained release microsphere through a solvent flow evaporation method using a cosolvent when manufacturing a microsphere in which a drug is sealed in a carrier comprising biodegradable polymers. Thus, early excessive release of a physiologically active substance is suppressed so the physiologically active substance can be continuously and uniformly released in the body.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets

Abstract

Disclosed is a method for preparing a longer sustained-release formulation containing bioactive substances. More particularly, the present invention provides a method for preparing longer sustained-release microcapsules comprising : adding an emulsion including bioactive substances, biocompatible polymer and polyvinylpyrrolidone to an aqueous solution.

IPC Classes  ?

• B01J 13/02 - Making microcapsules or microballoons